Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444066 | 0.84 | ALDH1A1 (0.42) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL20691937 | 0.81 | P2RY1 (0.36) | TYMP | |
| SCHEMBL24258586 | 0.80 | TAS1R3 (0.42) | P2RX3 | |
| SCHEMBL24258558 | 0.78 | ALDH1A1 (0.39) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL20671325 | 0.75 | ADORA3 (0.53) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL21539861 | 0.73 | ALDH1A1 (0.61) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL21636980 | 0.73 | ALDH1A1 (0.61) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL20691939 | 0.72 | P2RY1 (0.40) | P2RX3ALDH1A1 | |
| SCHEMBL21263957 | 0.70 | ALDH1A1 (0.41) | P2RX3HPRT1ADORA3ALDH1A1LMNA | |
| SCHEMBL9308280 | 0.70 | ALDH1A1 (0.60) | P2RX3HPRT1ADORA3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |